Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy

Nine pretreated patients aged >19 years with relapsed/refractory acute lymphoblastic leukemia (ALL) were treated with a combination of bortezomib plus chemotherapy before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Eight (88.9%) patients, including two Philadelphia chromosome-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Junmei, Wang, Chao, Song, Yongping, Liu, Yuzhang, Fang, Baijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472074/
https://www.ncbi.nlm.nih.gov/pubmed/26109875
http://dx.doi.org/10.2147/IJGM.S59537
_version_ 1782376999782711296
author Zhao, Junmei
Wang, Chao
Song, Yongping
Liu, Yuzhang
Fang, Baijun
author_facet Zhao, Junmei
Wang, Chao
Song, Yongping
Liu, Yuzhang
Fang, Baijun
author_sort Zhao, Junmei
collection PubMed
description Nine pretreated patients aged >19 years with relapsed/refractory acute lymphoblastic leukemia (ALL) were treated with a combination of bortezomib plus chemotherapy before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Eight (88.9%) patients, including two Philadelphia chromosome-positive ALL patients, achieved a complete remission. Furthermore, the evaluable patients have benefited from allo-HSCT after response to this reinduction treatment. We conclude that bortezomib-based chemotherapy was highly effective for adults with refractory/relapsed ALL before allo-HSCT. Therefore, this regimen deserves a larger series within prospective trials to confirm these results.
format Online
Article
Text
id pubmed-4472074
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44720742015-06-24 Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy Zhao, Junmei Wang, Chao Song, Yongping Liu, Yuzhang Fang, Baijun Int J Gen Med Original Research Nine pretreated patients aged >19 years with relapsed/refractory acute lymphoblastic leukemia (ALL) were treated with a combination of bortezomib plus chemotherapy before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Eight (88.9%) patients, including two Philadelphia chromosome-positive ALL patients, achieved a complete remission. Furthermore, the evaluable patients have benefited from allo-HSCT after response to this reinduction treatment. We conclude that bortezomib-based chemotherapy was highly effective for adults with refractory/relapsed ALL before allo-HSCT. Therefore, this regimen deserves a larger series within prospective trials to confirm these results. Dove Medical Press 2015-06-12 /pmc/articles/PMC4472074/ /pubmed/26109875 http://dx.doi.org/10.2147/IJGM.S59537 Text en © 2015 Zhao et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhao, Junmei
Wang, Chao
Song, Yongping
Liu, Yuzhang
Fang, Baijun
Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
title Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
title_full Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
title_fullStr Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
title_full_unstemmed Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
title_short Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
title_sort treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472074/
https://www.ncbi.nlm.nih.gov/pubmed/26109875
http://dx.doi.org/10.2147/IJGM.S59537
work_keys_str_mv AT zhaojunmei treatmentofrefractoryrelapsedadultacutelymphoblasticleukemiawithbortezomibbasedchemotherapy
AT wangchao treatmentofrefractoryrelapsedadultacutelymphoblasticleukemiawithbortezomibbasedchemotherapy
AT songyongping treatmentofrefractoryrelapsedadultacutelymphoblasticleukemiawithbortezomibbasedchemotherapy
AT liuyuzhang treatmentofrefractoryrelapsedadultacutelymphoblasticleukemiawithbortezomibbasedchemotherapy
AT fangbaijun treatmentofrefractoryrelapsedadultacutelymphoblasticleukemiawithbortezomibbasedchemotherapy

Ejemplares similares